Kogavant (Ticagrelor)

Kogavant (ticagrelor) is used in the antiplatelet therapy pathway for cardiovascular disease.

• Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke in patients presenting with ACS.
• ST-elevation myocardial infarction (STEMI): improves outcomes when added to standard care in STEMI patients.
• Non‑ST-elevation myocardial infarction (NSTEMI): lowers recurrent ischemic events in NSTEMI management.
• Unstable angina: decreases the incidence of further cardiac events in patients with unstable angina.
• Secondary prevention after myocardial infarction: prevents recurrent thrombotic events in post‑MI patients.

• Ticagrelor reversibly binds to the platelet P2Y12 ADP receptor, blocking ADP-mediated activation of the GPIIb/IIIa complex. This inhibition prevents platelet aggregation and thrombus formation without requiring metabolic activation, providing rapid and consistent antiplatelet effects across a broad patient population.

Ticagrelor may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dyspnea: shortness of breath, often transient.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Diarrhea: loose stools without severe dehydration.

Serious or Rare Side Effects

• Major bleeding: life‑threatening hemorrhage requiring medical intervention.
• Thrombotic thrombocytopenic purpura: rare hematologic disorder.
• Severe allergic reactions: anaphylaxis or angioedema.

Before prescribing ticagrelor, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Assess bleeding risk: review history of hemorrhage, recent surgery, or anticoagulant use.
• Monitor hepatic function: adjust use in patients with severe liver impairment.
• Evaluate renal function: caution in severe renal dysfunction.
• Avoid in patients with active pathological bleeding.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Ticagrelor interacts with several drug classes that can alter its antiplatelet efficacy or increase bleeding risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Concurrent anticoagulants (e.g., warfarin, DOACs): heighten bleeding risk.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise concentrations.
• Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): monitor for myopathy.
• Digoxin: increased serum levels may occur; monitor renal function.